Myelodysplastic syndromes tied to faster bone loss and lower survival
A prospective study followed 111 patients with myelodysplastic syndromes and 84 age-matched controls for three years. Patients already had lower bone density at baseline and continued to lose bone, and osteoporosis at the start was linked to poorer overall survival. The findings suggest bone aging may accelerate in MDS and highlight connections between blood formation and bone health.
MDS are cancers of the blood cell production system, mostly diagnosed in older people. In affected individuals, bone marrow cannot produce blood cells normally, so treatment often tracks blood counts and manages anemia or transfusion needs. Bone health has historically drawn less clinical attention in this group.
The BoHemE prospective study, launched in Dresden in 2016, compared 111 MDS patients with 84 comparison participants of similar age over three years. Besides lower baseline bone density and continued loss, researchers found a DNMT3A mutation in blood-producing cells linked to lower density, and low calcium more often in those with osteoporosis or low density. MDS may also accompany chronic inflammation and conditions such as heart attacks and Alzheimer's disease.
Because MDS mainly affects older adults, findings could matter to patients, caregivers, and clinicians who already manage anemia, transfusions, and age-related frailty. If bone loss is routinely considered alongside blood disease, some patients may receive earlier osteoporosis assessment or treatment, potentially improving mobility and quality of life. The results may also encourage broader thinking about aging, inflammation, and survival, though they do not yet prove that bone-directed care changes MDS outcomes.